SBIR/STTR Research Award

SBIR Phase II:Preventing Pneumothorax During Lung Biopsy Using a Novel Hydrogel

Award identifier 2022fcf3334f99decca52dd0669e61bf8ae7b75f3b55db1d350a6cbd5f2496fbAwarding agency National Science Foundation

Award amount

$1,000,000

Program and phase

SBIR · Phase II

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
PneumoNIX Medical Inc.
Proposal award date
2022-08-01
Contract end date
2024-07-31
UEI
LDHMBK6YPL91
Solicitation number
NSF 21-565
Topic code
BM

Research abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to improve patient outcomes, and reduce the morbidity and costs associated with lung collapse (pneumothorax) during computed tomography (CT)-lung biopsies used for screening lung cancer. Over 400,000 CT-guided lung biopsies are performed in the US, and more than 1.2 million worldwide. Management and treatment of symptomatic pneumothorax often requires multi-day hospital stays and costs on average of $15,000 per patient and $1.3 billion yearly worldwide. Preventing pneumothorax may increase access to lung cancer screenings by de-risking CT-guided lung biopsies and allowing smaller ambulatory surgery centers in remote geographies to perform the screening procedure. Currently, physicians collect limited biopsy samples due to the increased risk of pneumothorax with multiple biopsy passes. Preventing pneumothorax may allow physicians to collect a greater number of biopsy samples and provide sufficient tissue to personalize the cancer treatment and improve patient outcomes.This Small Business Innovation Research (SBIR) Phase II project is developing a novel biosealant that will reduce or eliminate pneumothorax. Pneumothorax — a collapsed lung - is the most common complication of computed tomography (CT)-guided lung biopsies, occurring in 20-40% of all CT-guided lung biopsies. The focus of the current investigation is to evaluate and demonstrate the possibility of using a biosealant and delivery device to seal needle tracts to prevent pneumothorax before it occurs, thereby filling a large gap in today’s solutions. Phase I data supports an injectable hydrogel formulation that successfully prevented pneumothorax in animal studies. In this Phase II project, the team seeks to refine the formulation for improved surgical performance and validate it with an animal model to demonstrate both efficacy and safety.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2019–2022). Reported award amounts total $1,225,000. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.